Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) EBIT Margin (2020 - 2025)

Caribou Biosciences has reported EBIT Margin over the past 6 years, most recently at 721.97% for Q4 2025.

  • Quarterly EBIT Margin rose 114972.0% to 721.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1329.37% through Dec 2025, up 33779.0% year-over-year, with the annual reading at 1329.37% for FY2025, 33779.0% up from the prior year.
  • EBIT Margin was 721.97% for Q4 2025 at Caribou Biosciences, up from 1337.58% in the prior quarter.
  • Over five years, EBIT Margin peaked at 61.84% in Q3 2023 and troughed at 1893.87% in Q1 2024.
  • The 5-year median for EBIT Margin is 881.92% (2023), against an average of 1086.31%.
  • Year-over-year, EBIT Margin tumbled -182739bps in 2024 and then surged 114972bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 797.38% in 2021, then decreased by -4bps to 828.22% in 2022, then dropped by -27bps to 1052.33% in 2023, then plummeted by -78bps to 1871.69% in 2024, then surged by 61bps to 721.97% in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBIT Margin are 721.97% (Q4 2025), 1337.58% (Q3 2025), and 1783.95% (Q2 2025).